ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
4 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
580
|
243K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
13 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
580
|
243K
|
13
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
16 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
580
|
243K
|
16
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
3 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
580
|
243K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
1 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
580
|
243K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
14 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
580
|
243K
|
14
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
9 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
580
|
243K
|
9
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Placement & ANREO to raise up to 13.6m
|
|
ma420
|
11 |
4.4K |
1 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
11
|
4.4K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Change of Director's Interest Notice - Taylor
|
|
ma420
|
6 |
1.9K |
7 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
6
|
1.9K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
12 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
580
|
243K
|
12
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
8 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
580
|
243K
|
8
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Placement & ANREO to raise up to 13.6m
|
|
ma420
|
11 |
4.4K |
4 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
11
|
4.4K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
33K |
8 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
132
|
33K
|
8
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
21 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
580
|
243K
|
21
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Application for quotation of securities - CU6
|
|
ma420
|
5 |
1.9K |
3 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
5
|
1.9K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
33K |
3 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
132
|
33K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
12 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
580
|
243K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
23K |
6 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
23K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.7K |
0 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
21
|
6.7K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.7K |
3 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
21
|
6.7K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
23K |
29 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
23K
|
29
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
15K |
0 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
15K
|
0
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
15K |
1 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
15K
|
1
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
15K |
9 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
15K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
663 |
242K |
26 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
663
|
242K
|
26
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.7K |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.7K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
580 |
243K |
18 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
580
|
243K
|
18
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Phase 2 blood cancer trial fully recruited
|
|
ma420
|
28 |
8.6K |
4 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
28
|
8.6K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
483 |
176K |
6 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
483
|
176K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
33K |
22 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
33K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
23K |
21 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
81
|
23K
|
21
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.7K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.7K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.7K |
23 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.7K
|
23
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Change of Director's Interest Notice - HA & SP
|
|
ma420
|
8 |
4.0K |
3 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
8
|
4.0K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.7K |
15 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.7K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
33K |
21 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
33K
|
21
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
33K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
33K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
483 |
176K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
483
|
176K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow)
|
|
ma420
|
68 |
15K |
9 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
68
|
15K
|
9
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Phase 2 blood cancer trial fully recruited
|
|
ma420
|
28 |
8.6K |
10 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
28
|
8.6K
|
10
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Trading Halt
|
|
ma420
|
4 |
779 |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
4
|
779
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
483 |
176K |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
483
|
176K
|
1
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Trading Halt
|
|
ma420
|
4 |
779 |
0 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
4
|
779
|
0
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Further Significant Improvement in Rett Syndrome Patients
|
|
ma420
|
15 |
4.1K |
8 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
15
|
4.1K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow)
|
|
ma420
|
68 |
15K |
15 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
68
|
15K
|
15
|
|
ASX - By Stock
|
COV |
Re:
Ann: CLEO Selects U.S. Clinical Trial Sites
|
|
ma420
|
8 |
4.3K |
8 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
8
|
4.3K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow)
|
|
ma420
|
68 |
15K |
10 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
68
|
15K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
33K |
6 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
132
|
33K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Placement
|
|
ma420
|
18 |
3.9K |
5 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
18
|
3.9K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Placement
|
|
ma420
|
18 |
3.9K |
3 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
18
|
3.9K
|
3
|
|